1608140-48-2 Usage
General Description
C34H54N2O14, also known as "Nucleomorphin", is a chemical compound with a molecular formula of C34H54N2O14. It is a synthetic peptide derivative of morphine that exhibits an analgesic effect but with a lower potential for tolerance and dependence. Nucleomorphin is thought to function as a mixed agonist-antagonist at opioid receptors, which may contribute to its reduced side effects compared to traditional opioids. C34H54N2O14 has been studied for its potential as a novel pain management medication with improved safety and efficacy profiles. Its unique structure and pharmacological properties make it a promising candidate for further research and development in the field of pain relief.
Check Digit Verification of cas no
The CAS Registry Mumber 1608140-48-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,0,8,1,4 and 0 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1608140-48:
(9*1)+(8*6)+(7*0)+(6*8)+(5*1)+(4*4)+(3*0)+(2*4)+(1*8)=142
142 % 10 = 2
So 1608140-48-2 is a valid CAS Registry Number.
1608140-48-2Relevant articles and documents
SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION
-
Page/Page column 104, (2016/04/26)
The present invention relates to a compound comprising an alpha-end and an omega-end, the compound comprising on the alpha-end a reactive group Qlcapable of reacting with a functional group F1present on a biomolecule and on the omega-end a target molecule, the compound further comprising a group according to formula (1) or a salt thereof: Said compound may also be referred to as a linker-conjugate. The invention also relates to a process for the preparation of a bioconjugate, the process comprising the step of reacting a reactive group Q1of a linker-conjugate according to the invention with a functional group F1of a biomolecule. The invention further relates to a bioconjugate obtainable by the process according to the invention. In a preferred embodiment, the invention concerns a process for the preparation of a bioconjugate via a cycloaddition, such as a (4+2)-cycloaddition (e.g. a Diels-Alder reaction) or a (3+2)-cycloaddition (e.g. a 1,3-dipolar cycloaddition).
